Connecticut 2019 2019 Regular Session

Connecticut Senate Bill SB00033 Comm Sub / Bill

Filed 03/07/2019

                     
 
 
LCO No. 5589   	1 of 2 
 
General Assembly  Committee Bill No. 33  
January Session, 2019  
LCO No. 5589 
 
 
Referred to Committee on INSURANCE AND REAL ESTATE  
 
 
Introduced by:  
(INS)  
 
 
 
AN ACT CONCERNING HE ALTH INSURANCE COVERAGE O F 
ORALLY AND INTRAVENO USLY ADMINISTERED PR ESCRIPTION 
DRUGS. 
Be it enacted by the Senate and House of Representatives in General 
Assembly convened: 
 
Section 1. (NEW) (Effective January 1, 2020) Each individual health 1 
insurance policy providing coverage of the type specified in 2 
subdivisions (1), (2), (4), (11), (12) and (16) of section 38a-469 of the 3 
general statutes delivered, issued for delivery, renewed, amended or 4 
continued in this state on or after January 1, 2020, providing coverage 5 
for prescription drugs shall provide coverage for orally administered 6 
prescription drugs on a basis that is no less favorable than the basis on 7 
which such policy provides coverage for intravenously administered 8 
prescription drugs. 9 
Sec. 2. (NEW) (Effective January 1, 2020) Each group health insurance 10 
policy providing coverage of the type specified in subdivisions (1), (2), 11 
(4), (11), (12) and (16) of section 38a-469 of the general statutes 12 
delivered, issued for delivery, renewed, amended or continued in this 13 
state on or after January 1, 2020, providing coverage for prescription 14 
drugs shall provide coverage for orally administered prescription 15 
drugs on a basis that is no less favorable than the basis on which such 16    
Committee Bill No.  33 
 
 
LCO No. 5589   	2 of 2 
 
policy provides coverage for intravenously administered prescription 17 
drugs. 18 
This act shall take effect as follows and shall amend the following 
sections: 
 
Section 1 January 1, 2020 New section 
Sec. 2 January 1, 2020 New section 
 
Statement of Purpose:   
To require health insurance policies providing coverage for 
prescription drugs to provide coverage for orally administered 
prescription drugs on a basis that is no less favorable than the basis on 
which such policies provide coverage for intravenously administered 
prescription drugs. 
[Proposed deletions are enclosed in brackets. Proposed additions are indicated by underline, 
except that when the entire text of a bill or resolution or a section of a bill or resolution is new, it is 
not underlined.] 
 
Co-Sponsors:  SEN. LOONEY, 11th Dist.  
 
S.B. 33